JLJ648 

JLJ648 is a Gag-Pol dimerizer with antiviral activity. JLJ648 can inhibit HIV replication and induce infected cell pyroptosis. JLJ648 can be used for the research of infection, such as HIV (human immunodeficiency virus)^[1].

JLJ648 (3 days) inhibits HIV-1 replication in MT-2 cells with an EC₅₀ of 1.6 nM^[1].
JLJ648 shows low cytotoxicity in MT-2 and THP-1 cells (CC₅₀>100 μM) and a CC₅₀ of 22.9 μM in primary CD4⁺ T cells^[1].
JLJ648 (17 h) promotes the homodimerization of recombinant HIV-1 RT p66 subunit with an EC₅₀ of 95 nM^[1].
JLJ648 (3-4 h) induces HIV protease-dependent pyroptosis in THP-1 clone14 cells and HIV-infected primary CD4⁺ T cells, with an EC₅₀ of 86 nM^[1].
JLJ648 (50 μM, 12 h) binds to HIV-1 RT p66 to form two oligomeric structures, subunits in catalytic/structural conformations and "infinity knot"-shaped homotetramer^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

415.46

C₂₃H₁₇N₃O₃S

S=C(N1)C=CN(CCOC2=C(OC3=CC=CC4=C3C=CC(C#N)=C4)C=CC=C2)C1=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Hollander K, et al. Mechanistic basis for a novel dual-function Gag-Pol dimerizer potentiating CARD8 inflammasome activation and clearance of HIV-infected cells. NPJ Drug Discov. 2025;2(1):22.  [Content Brief]